Receive news by e-mail

#
 

Enter your e-mail in the field below to receive directly the news that appears on this page.

 

topics : related - all Explore

Shopping Categories

  1. 1. Cell Phones
  2. 2. Smartphones
  3. 3. Digital Cameras
  4. 4. Laptop Computers
  5. 5. Processors
  6. 6. Motherboards
  7. 7. LCD Monitors
  8. 8. Graphics Cards
  9. 9. Digital Camcorders
  10. 10. GPS
  11. 11. Printers
  12. 12. Desktop Computers
  13. 13. Sedans
  14. 14. Coupes & Convertibles
  15. 15. 4x4

Wikio Shopping

  1. 1. Automotive
  2. 2. Beauty & Fragrances
  3. 3. Books
  4. 4. Car/Motorbike
  5. 5. CD
  6. 6. Clothing, Accessories & Shoes
  7. 7. Communication
  8. 8. Computers
  9. 9. DVD
  10. 10. Electronics
  11. 11. Flowers & Gifts
  12. 12. Gourmet & Foods
  13. 13. Health & Personal Care
  14. 14. Home & Garden
  15. 15. Hotels
  16. 16. Household Appliances
  17. 17. Jewelry & Watches
  18. 18. Musical Instruments
  19. 19. Sports & Outdoors
  20. 20. Toys & Baby
  21. 21. Video Games

Participate



Nektar Therapeutics



Sort by : relevance - date - popularity
3Vote!

Lorianne Masuoka Made SVP at Nektar Therapeutics

Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer. Lorianne, who holds an M.D. from the University of California, Davis and completed her fellowship at the Yale School of...

5Vote!

Nektar names Masuoka chief medical officer

Nektar Therapeutics on Monday announced the promotion of Dr. Lorianne Masuoka to senior vice president and chief medical officer. (NKTR)

4Vote!

Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer

SAN CARLOS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer. Dr. Masuoka will report directly to Nektar's President and Chief Executive Officer, Howard W. Robin.

5Vote!

Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer

SAN CARLOS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer. Dr.

3Vote!

Nektar Therapeutics Reports Operating Results (10-Q)

By 10qk. Nektar Therapeutics ( NKTR ) filed Quarterly Report for the period ended 2009-09-30. Read more » »

5Vote!

Nektar Therapeutics Reports Third Quarter 2009 Financial Results

SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2009.

5Vote!

Nektar Therapeutics Reports Third Quarter 2009 Financial Results

SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2009.

4Vote!

Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets

SAN CARLOS, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00...

5Vote!

Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets

SAN CARLOS, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009, after the close of U.S.-based financial markets.

4Vote!

Nektar Completes Enrollment Ahead Of Schedule In Phase 2 Clinical Trial Evaluating NKTR-102 In Patients With Platinum-Resistant Ovarian Cancer

Nektar Therapeutics (Nasdaq: NKTR) announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

5Vote!

Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix

PHOENIX and SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

5Vote!

AstraZeneca: Nektar Deal to Add Value

Zacks.com submits: Recently, AstraZeneca ( AZN ) entered into a licensing deal with Nektar Therapeutics ( NKTR ) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a Phase II trial for the treatment of opioid-induced constipation, the latter, in early stage of development, is intended to treat pain without constipation side effects. Nektar will receive an upfront...

4Vote!

Zacks Bull and Bear of the Day Highlights: Skyworks Solutions, Valero Energy, AstraZeneca, Nektar Therapeutics and Wyeth

CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights Skyworks Solutions (SWKS) as the Bull of the Day and Valero Energy (VLO) the Bear of the Day. In addition, Zacks Equity Research provides analysis on AstraZeneca (AZN), Nektar Therapeutics (NKTR) and Wyeth (WYE). Full analysis of all these stocks is available at http://at.zacks.com/?id=2676. Here is a synopsis of all five stocks: Bull of the...

3Vote!

AstraZeneca inks licensing deal with US drug firm

AstraZeneca and US-based Nektar Therapeutics have entered into a worldwide licencing agreement for two drug development programmes, NKTR-118 and NKTR-119.

4Vote!

Nektar on a roll as ovarian cancer drug shows promise

Yesterday shares of Nektar Therapeutics jumped 13 percent on the news that the developer had struck a $1.5 billion licensing deal for two of its development programs with AstraZeneca. This morning its shares rose 11 percent after investigators said a small, early-stage trial of a new ovarian cancer drug produced promising results. Two of the five patients in the trial of NKTR-102 were evaluable for...